ASH – 65th American Society of Hematology (ASH) Annual Meeting and Exposition – Dec 10, 2023

E. Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, 65th ASH Annual Meeting and Exposition, San Diego, CA. Dec 10 2023

IMS – International Myeloma Society – 20th Annual Meeting – Oral Presentation (AL Amyloidosis) – Sep 27-30, 2023

E. Lebel, S. Kfir Erenfeld, N. Asherie, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023 Sep 27-30.

IMS – International Myeloma Society – 20th Annual Meeting – Poster Presentation (Multiple Myeloma) – Sep 27-30, 2023

E. Lebel, N. Asherie, S. Kfir Erenfeld, S. Grisariu, B. Avni, S. Elias, M. Assayag, T. Dubnikov, N. Zalcman, M. Pick, E. Zimran, A. Shaulov, Y. Cohen, I. Avivi, C. Cohen, P. Stepensky, M.E. Gatt. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. Sep 27-30 2023.  

ASGCT – American Society of Gene & Cell Therapy — 29th Annual Meeting – Late-Breaking Oral Presentation – May 19, 2023

Asherie N. et al, BCMA-Targeted CART (HBI0101), a Safe and Efficacious Novel Modality of Treatment for Light Chain Amyloidosis (AL) Patients. Oral Presentation. ASGCT – American Society of Gene & Cell Therapy 29 ^th Annual Meeting. May 19, 2023.

ASGCT – American Society of Gene & Cell Therapy — 29th Annual Meeting – Late-Breaking Abstract – May 19, 2023

Asherie N., Kfir-Erenfeld S., Lebel E., Assayag M., Grisariu S., Avni B., Gatt ME, Stepensky, P. BCMA-Targeted CART (HBI0101), a Safe and Efficacious Novel Modality of Treatment for Light Chain Amyloidosis (AL) Patients. Late Breaking Abstract. ASGCT – American Society of Gene & Cell Therapy 29 ^th Annual Meeting. May 19, 2023.

European Society for Blood and Marrow Transplantation 49th Annual Meeting – Apr 23-26, 2023

M. Assayag , N. Asherie, S. Kfir Erenfeld, B. Avni, T. Dubnikov, N. Zalcman, E. Lebel, E. Zimran, A. Shaulov, M. Pick, Y. Cohen, I. Avivi, C. Cohen, M. Gatt, S. Grisariu, P. Stepensky. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26.

5th European CAR T-cell Meeting – 47 Patient Clinical Data Poster Presentation – Feb 9-11, 2023

Assayag M, Asherie N, Kfir-Erenfeld S, Avni B, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11.

Phase 1 – Multiple Myeloma

Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.

Editorial – Sjöstrand M, Sadelain M. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. Haematologica. 2023. doi: 10.3324/haematol.2022.282053. Epub ahead of print. PMID: 36794501. (PDF link)

Phase 1 –  AL Amyloidosis

Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221.

Preclinical

Harush O, Asherie N, Kfir-Erenfeld S, Adler G, Barliya T, Assayag M, Gatt ME, Stepensky P, Cohen CJ. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica. 2022 Oct 1;107(10):2395-2407. doi: 10.3324/haematol.2021.280169. PMID: 35354252; PMCID: PMC9521250.